-+ 0.00%
-+ 0.00%
-+ 0.00%

C4 Therapeutics to present Phase 1 biomarker data on cemsidomide plus dexamethasone in multiple myeloma trial at IMS meeting

PUBT·09/03/2026 11:02:24
Listen to the news
C4 Therapeutics to present Phase 1 biomarker data on cemsidomide plus dexamethasone in multiple myeloma trial at IMS meeting
  • C4 Therapeutics scheduled new biomarker results from its Phase 1 relapsed/refractory multiple myeloma trial for presentation on September 25, 2026.
  • Data cover cemsidomide with dexamethasone, highlighting immunomodulatory effects on T cells and natural killer cells across tested once-daily doses.
  • Findings support cemsidomide’s positioning as a potential combination partner for immune-based therapies in multiple myeloma.
  • Poster slated for the 23rd International Myeloma Society Annual Meeting in Glasgow, running September 23-26, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. C4 Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609030700PRIMZONEFULLFEED9820753) on September 03, 2026, and is solely responsible for the information contained therein.